This page shows the latest Daniel O'Day news and features for those working in and with pharma, biotech and healthcare.
treated with the drug, according to Gilead's chief executive officer Daniel O’Day.
HDV is a devastating disease with high unmet medical need. With Hepcludex we have the opportunity to address that need with a first-in-class therapy,” said Daniel O’Day, chairman
Daniel O’Day, even further into question.
This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio,” said Daniel O’Day, chairman and chief executive officer of Gilead.
Tizona is pursuing first-in-class cancer immunotherapies that could make an important difference in oncology by helping patients who don’t respond to current checkpoint inhibitors,” said Daniel O’Day,
Gilead is committed to accessing the world’s best innovation in immuno-oncology and our agreement with Arcus further demonstrates that commitment,” said Daniel O’Day, chairman and chief executive officer, ... Gilead has been expanding into
More from news
Approximately 1 fully matching, plus 35 partially matching documents found.
A number of clinical trials evaluating remdesivir’s efficacy in COVID-19 are currently underway in China and the US, with Gilead CEO Daniel O’Day commenting that “initial data” is ... have activity for,” added O’Day.
The pipeline-building deal is the largest under new Gilead chief executive Daniel O’Day, who took the helm of Gilead in March 2019, and includes a massive $3.95bn upfront,
Having been stung by drugs that shine in RCTs but under deliver in day-to-day practice, these stakeholders want to know what effect therapies will have on people in the ... The takeover was driven by a belief that “regulatory-grade real-world evidence
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
We are very pleased to welcome Sandra Horning to our Board of Directors,” said Daniel O’Day (pictured right), chairman and chief executive officer of Gilead Sciences.
At Roche, Daniel O'Day, currently chief operating officer Roche Diagnostics has been appointed as Soriot's replacement as chief operating officer of Roche Pharma effective September 1, 2012. ... O'Day will be succeeded by Roland Diggelmann, currently
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
No results were found
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...